Penumbra, Inc. (PEN)
322.76
-0.34
(-0.10%)
USD |
NYSE |
Sep 01, 16:00
322.76
0.00 (0.00%)
After-Hours: 20:00
Penumbra Research and Development Expense (Annual) : 69.43M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 69.43M |
| December 31, 2024 | 94.78M |
| December 31, 2023 | 84.42M |
| December 31, 2022 | 79.41M |
| December 31, 2021 | 104.55M |
| December 31, 2020 | 87.55M |
| December 31, 2019 | 51.72M |
| Date | Value |
|---|---|
| December 31, 2018 | 36.16M |
| December 31, 2017 | 31.66M |
| December 31, 2016 | 23.88M |
| December 31, 2015 | 18.03M |
| December 31, 2014 | 15.58M |
| December 31, 2013 | 14.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp. | 2.052B |
| Globus Medical, Inc. | 146.94M |
| Teleflex, Inc. | 144.78M |
| Abbott Laboratories | 2.889B |
| AngioDynamics, Inc. | 29.45M |